More pos­i­tive PhI­II da­ta set stage for Scynex­is' vagi­nal yeast in­fec­tion drug ap­proval

Months af­ter un­veil­ing da­ta that showed its lead ex­per­i­men­tal com­pound, ibrex­a­fungerp, helped pa­tients with vagi­nal yeast in­fec­tions, an­ti­fun­gal drug de­vel­op­er Scynex­is is one step clos­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER